• Wed news: Novo and Viking heat up MASH space. New Pfizer R&D chief. Trump and the Biosecure Act. Sage Huntington’s prospect flunks trial. Dr. Oz to run CMS. See more on our front page


What a disaster the HCV division is

Quote




Anonymous said:
This thread is ridiculous! Sure, there are issues like stupid metrics, field coaching reports, new managers trying to prove themselves. The marketing is a bit of a disaster, as they continue to screw everything up that they touch, like Moderiba, and Oraquick. They never tell you what's going on with speakers and the MSL's are terrible. But in all honesty, it's not that much different than most companies. Most of the people are good folks and get along. There isn't a lot of backstabbing, the leadership is a nice group of people and I like my manager and regional. There are a lot worse places to work, and this HCV division is a huge step up from my former division in rhuem.
Click to expand...

Why do you say the "MSLs are terrible?
 




Where is Lootzie on all of this? He is the VP and its his job to make it RIGHT!!! I often feel we are not being told the truth on timing for approval, sales potential, competitive edge, bonus $s, KOL support, etc., etc,! My DM is a goofy one who seems more interested in following sports than business. Scary times!!! We need LEADERSHIP!!
 








Anonymous said:
If reps don't influence sales then why do companies spend millions upon millions on reps?
Click to expand...

Just to kiss docs' asses basically. In the current medical environment, reps have less impact then ever. The ass kissing may get you a few scripts but formulary/wholesale cost is what makes the decision for the docs when there are multiple products available for the same indication from several different pharma companies.
That's the whole point behind the mystery of the vanishing rep jobs over the last several years. Sure, for a new launch you need bodies trying to get 3 seconds of a docs time to introduce the new drug. That is only novel to them for a very limited time. Then the rep moves into the next role as "pain in the ass" and "pizza tosser". The Sunshine Act has greatly curtailed even this dipshit role.
The net cost to the patient and the insurers' cost will ultimately determine who wins the biz. Between Ocare and Medicare and commercial plans all squeezing costs, that is the true determining factor.
Gilly has left a lot of opportunity for others to compete, cost wise. But that is easier said then done. They too can cut their prices a lot to stay in the game.
Where is the rep in this whole scenario? Not needed for long.
 




Anonymous said:
Where is Lootzie on all of this? He is the VP and its his job to make it RIGHT!!! I often feel we are not being told the truth on timing for approval, sales potential, competitive edge, bonus $s, KOL support, etc., etc,! My DM is a goofy one who seems more interested in following sports than business. Scary times!!! We need LEADERSHIP!!
Click to expand...

No, Lutz does not have to make anything right. He needs sales. That's it, that all. Sales.
 




Anonymous said:
Just to kiss docs' asses basically. In the current medical environment, reps have less impact then ever. The ass kissing may get you a few scripts but formulary/wholesale cost is what makes the decision for the docs when there are multiple products available for the same indication from several different pharma companies.
That's the whole point behind the mystery of the vanishing rep jobs over the last several years. Sure, for a new launch you need bodies trying to get 3 seconds of a docs time to introduce the new drug. That is only novel to them for a very limited time. Then the rep moves into the next role as "pain in the ass" and "pizza tosser". The Sunshine Act has greatly curtailed even this dipshit role.
The net cost to the patient and the insurers' cost will ultimately determine who wins the biz. Between Ocare and Medicare and commercial plans all squeezing costs, that is the true determining factor.
Gilly has left a lot of opportunity for others to compete, cost wise. But that is easier said then done. They too can cut their prices a lot to stay in the game.
Where is the rep in this whole scenario? Not needed for long.
Click to expand...

With Gileads product advantages, they will not need to meet low ball prices. Their one pill solution with no errant side effect or interaction concerns, will run the whole show.
 








Anonymous said:
With Gileads product advantages, they will not need to meet low ball prices. Their one pill solution with no errant side effect or interaction concerns, will run the whole show.
Click to expand...

So true. A small price concession on Gilly's part is all that will be needed to consume this market. Abbvie is late to the dance and out of step competitively speaking.
 








Anonymous said:
Just to kiss docs' asses basically. In the current medical environment, reps have less impact then ever. The ass kissing may get you a few scripts but formulary/wholesale cost is what makes the decision for the docs when there are multiple products available for the same indication from several different pharma companies.
That's the whole point behind the mystery of the vanishing rep jobs over the last several years. Sure, for a new launch you need bodies trying to get 3 seconds of a docs time to introduce the new drug. That is only novel to them for a very limited time. Then the rep moves into the next role as "pain in the ass" and "pizza tosser". The Sunshine Act has greatly curtailed even this dipshit role.
The net cost to the patient and the insurers' cost will ultimately determine who wins the biz. Between Ocare and Medicare and commercial plans all squeezing costs, that is the true determining factor.
Gilly has left a lot of opportunity for others to compete, cost wise. But that is easier said then done. They too can cut their prices a lot to stay in the game.
Where is the rep in this whole scenario? Not needed for long.
Click to expand...

There must be a reason that company's spend so much on reps.
 












Kadmon Layoffs

Now that Kadmon has alienated their employes and customers. It might be a good time to revisit ModaRiba. It will be much easier to get a foot in the door with Moda than with our DAA regiment
 




























Top Bottom
Back
Quote